Drug Stock: Analysts See It Surging 60%, Eyes Fresh Entry | Investor's Business Daily Stocks have been broadly under pressure of late. But drug stock Innoviva (INVA) has used this as an opportunity to build a bullish base as analysts see hearty price gains ahead. The firm originally served to manage royalty streams from respiratory drugs codeveloped with health care giant GlaxoSmithKline (GSK). These include the likes of blockbuster treatments Trelegy Ellipta and Breo Ellipta. X Here's How Stock Screens ...